Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Polyrizon Ltd. ( (PLRZ) ) has issued an update.
On December 11, 2025, Polyrizon Ltd. announced promising results from preclinical studies of its intranasal naloxone hydrogel, showcasing rapid permeation kinetics that match existing products while offering improved mucosal retention. These findings suggest that Polyrizon’s naloxone hydrogel could advance in development, potentially enhancing treatment reliability in opioid overdose interventions, amidst a growing global naloxone market driven by increasing public health initiatives.
More about Polyrizon Ltd.
Polyrizon Ltd. is a biotechnology company specializing in the development of innovative intranasal products, particularly focusing on medical device hydrogels that form a protective barrier in the nasal cavity. Their proprietary technologies, Capture and Contain (C&C) and Trap and Target (T&T), are designed to enhance mucosal retention and facilitate the nasal delivery of active pharmaceutical ingredients.
Average Trading Volume: 3,188,125
Technical Sentiment Signal: Sell
Current Market Cap: $17.09M
Find detailed analytics on PLRZ stock on TipRanks’ Stock Analysis page.